# NCT02362594 (NCT02362594)

> Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02362594
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Melanoma
- Interventions: pembrolizumab; placebo
- Enrollment: 1019
- Primary outcome: Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among All Participants
- Primary outcome: Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression

## Commentary we found

- Podcasts: 18
- YouTube: 4
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02362594

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02362594", "email": "<work email>"}; the inbox owner confirms by the emailed link.